Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001213900-20-013951
Filing Date
2020-06-02
Accepted
2020-06-02 17:00:44
Documents
4
Group Members
KFIR SILBERMAN

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ea122591-13dpure_therapixbio.htm SC 13D 196020
2 DEMAND LETTER TO CONVENE A SPECIAL GENERAL MEETING OF THE SHAREHOLDERS OF THE RE ea122591ex1_therapixbio.htm EX-99.1 16199
3 POSITION STATEMENT IN CONNECTION WITH THE DEMAND LETTER TO CONVENE A SPECIAL GEN ea122591ex2_therapixbio.htm EX-99.2 18110
4 JOINT FILING AGREEMENT BY AND AMONG L.I.A. PURE CAPITAL LTD. AND KFIR SILBERMAN, ea122591ex3_therapixbio.htm EX-99.3 4384
  Complete submission text file 0001213900-20-013951.txt   236211
Mailing Address 4 ARIEL SHARON STREET HASHAHAR TOWER, 16TH FLOOR GIV?ATAYIM L3 5320047
Business Address 4 ARIEL SHARON STREET HASHAHAR TOWER, 16TH FLOOR GIV?ATAYIM L3 5320047 972-3-6167055
Therapix Biosciences Ltd. (Subject) CIK: 0001611746 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-89951 | Film No.: 20937896
SIC: 2834 Pharmaceutical Preparations

Mailing Address 20 RAOUL WALENBERG ST TEL AVIV L3 6971916
Business Address 20 RAOUL WALENBERG ST TEL AVIV L3 6971916 972-3-7175777
L.I.A. Pure Capital Ltd (Filed by) CIK: 0001749628 (see all company filings)

EIN.: 000000000
Type: SC 13D